Danaher Q4 Earnings Miss; Shares Drop 5-8%

Danaher Corporation's fourth-quarter earnings report showed mixed results, with adjusted EPS of $2.14 falling short of Wall Street estimates, leading to a 5-8% drop in share prices. Despite overall revenues of $6.54 billion surpassing forecasts, the company's guidance for Q1 2025 anticipates a decline in non-GAAP core revenue, attributed to weak demand from biotech clients and cautious spending from smaller customers. The diagnostics segment saw a decline, while the life sciences and biotechnology segments reported growth. The company remains optimistic about long-term growth due to its portfolio transformation, expecting a 3% increase in core revenue for the full year 2025. Danaher's stock had previously outperformed the market, but recent inconsistent results have led to a reevaluation of its position by investors.